GLSI
NASDAQ · Biotechnology
Greenwich Lifesciences Inc
$23.37
-0.38 (-1.60%)
Open$23.63
Previous Close$23.75
Day High$24.00
Day Low$23.35
52W High$34.10
52W Low$7.78
Volume—
Avg Volume104.7K
Market Cap343.18M
P/E Ratio—
EPS$-1.56
SectorBiotechnology
Analyst Ratings
Strong Buy
8 analysts
Price Target
+45.7% upside
Current
$23.37
$23.37
Target
$34.05
$34.05
$25.54
$34.05 avg
$45.13
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 64.12M | 62.89M | 59.76M |
| Net Income | 10.06M | 8.97M | 9.50M |
| Profit Margin | 15.7% | 14.3% | 15.9% |
| EBITDA | 19.32M | 16.62M | 17.12M |
| Free Cash Flow | 7.72M | 11.60M | 9.03M |
| Rev Growth | -9.0% | -7.6% | +0.6% |
| Debt/Equity | 0.70 | 0.55 | 0.67 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $234.76 | +2.07% | 105.2 | 382.49B |
| AMGN | Amgen Inc | $347.01 | +0.66% | 23.4 | 182.21B |
| GILD | Gilead Sciences Inc | $125.05 | +0.14% | 16.7 | 153.66B |
| VRTX | Vertex Pharmaceuticals Inc | $468.42 | +0.35% | 26.4 | 114.63B |
| REGN | Regeneron Pharmaceuticals | $618.03 | +0.90% | 14.5 | 63.95B |
| ALNY | Alnylam Pharmaceuticals Inc | $288.18 | +0.62% | 64.3 | 37.13B |